Current cardiology reports · 2026
Eosinophilia and the Heart: Evolving Concepts.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Habasko Jan, Kuchynka Petr, Bonatto Mayara Elisa, Palecek Tomas
Аннотация
PURPOSE OF REVIEW: This review summarises recent advances in cardiac involvement in eosinophilia, with particular emphasis on pathophysiology, diagnostic challenges and therapeutic options.
RECENT FINDINGS: Up to 43% of patients with histologically proven eosinophilic myocarditis (EM) have no evidence of peripheral blood eosinophilia. Aberrations in the interleukin-5 pathway are central to the pathophysiology of EM. In addition, other contributing factors for specific aetiologies are being recognised, such as susceptibility loci GPA33 and IRF1/IL5 in patients with ANCA-negative eosinophilic granulomatosis with polyangiitis. There is growing evidence for interleukin-5 pathway inhibition in disease management. EM carries a high mortality risk and thus, early identification of these patients, multidisciplinary collaboration and early initiation of targeted therapy are of utmost importance. Future studies are needed to investigate other therapeutic options, including long-acting anti-interleukin-5 inhibitors.
RECENT FINDINGS: Up to 43% of patients with histologically proven eosinophilic myocarditis (EM) have no evidence of peripheral blood eosinophilia. Aberrations in the interleukin-5 pathway are central to the pathophysiology of EM. In addition, other contributing factors for specific aetiologies are being recognised, such as susceptibility loci GPA33 and IRF1/IL5 in patients with ANCA-negative eosinophilic granulomatosis with polyangiitis. There is growing evidence for interleukin-5 pathway inhibition in disease management. EM carries a high mortality risk and thus, early identification of these patients, multidisciplinary collaboration and early initiation of targeted therapy are of utmost importance. Future studies are needed to investigate other therapeutic options, including long-acting anti-interleukin-5 inhibitors.